De processu cognitionis humanae

Invocatio: Adfulgente gratia divina.

De amore sui ordinato

Invocatio: A.S.S.T.

De affectibus humanis

Invocatio: J.N.S.S.T.

De gradibus cognitionis humanae

Invocatio: Q.F.F.Q.S.

De subsidiis memoriae

Invocatio: Q.F.F.Q.E.J.D.T.O.M.

De libertate animae, principio rationis sufficientis consentanea

Invocatio: Q.B.V.D.

De praejudiciis

Invocatio: J.J.S.A.F.

Quod

Dedicatio: Fabianus Wrede, Laurentius Johannes Ehrenmalm, Adamus Skyts, Samuel Schulten, David Benedict Cneif [ruots. runo].

Exercitium academicum de usu quem praestat psychologia oeconomo quod cons. ampl. fac. philos. in Acad. Auraicae praeside viro maxime reverendo atque amplissimo

I.N.J.

Animadversiones circa fallacias

Invocatio: D.F.G.

De cognitione animae per experientiam

Invocatio: Auspiciis faustis.

Läran om den absoluta friheten vid sin öfvergång till ändlighet i viljan

Painovuosi nimekkeestä.

De perfectione voluntatis

Invocatio: Q.B.V.D.O.M.

Läran om den absoluta friheten vid sin öfvergång till ändlighet i viljan

Dedicatio: Zacharias Forsman, Eva Aurora Forsman, f. Estlander.

Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass

Twenty-four surgical patients of both sexes without cardiac, hepatic, renal or endocrine dysfunctions were divided into two groups: 10 cardiac surgical patients submitted to myocardial revascularization and cardiopulmonary bypass (CPB), 3 females and 7 males aged 65 ± 11 years, 74 ± 16 kg body weight, 166 ± 9 cm height and 1.80 ± 0.21 m2 body surface area (BSA), and control, 14 surgical patients not submitted to CPB, 11 female and 3 males aged 41 ± 14 years, 66 ± 14 kg body weight, 159 ± 9 cm height and 1.65 ± 0.16 m2 BSA (mean ± SD). Sodium diclofenac (1 mg/kg, im Voltaren 75® twice a day) was administered to patients in the Recovery Unit 48 h after surgery. Venous blood samples were collected during a period of 0-12 h and analgesia was measured by the visual analogue scale (VAS) during the same period. Plasma diclofenac levels were measured by high performance liquid chromatography. A two-compartment open model was applied to obtain the plasma decay curve and to estimate kinetic parameters. Plasma diclofenac protein binding decreased whereas free plasma diclofenac levels were increased five-fold in CPB patients. Data obtained for analgesia reported as the maximum effect (EMAX) were: 25% VAS (CPB) vs 10% VAS (control), P<0.05, median measured by the visual analogue scale where 100% is equivalent to the highest level of pain. To correlate the effect versus plasma diclofenac levels, the EMAX sigmoid model was applied. A prolongation of the mean residence time for maximum effect (MRTEMAX) was observed without any change in lag-time in CPB in spite of the reduced analgesia reported for these patients, during the time-dose interval. In conclusion, the extent of plasma diclofenac protein binding was influenced by CPB with clinically relevant kinetic-dynamic consequences